FrancophonIA/ELRC3.0 huggingface dataset:
English: Metabolism and nutrition disorders diabetes mellitus, hyperglycaemic conditions, hyperkalaemia anorexia, metabolic acidoses, other electrolyte abnormalities, hyponatraemia, fluid overload, hyperuricaemia, hypomagnesaemia, hypokalaemia, hypocalcemia, appetite decreased, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, hypophosphateaemia dehydration, hypoglycaemia, hypoproteinaemia, hyperphosphataemia
Maltese: - Tnaqqis fl-għadd ta' ċelluli tad-demm (plejtlits, ċelluli ħomor jew bojod tad-demm), żieda fl għadd ta' ċelluli bojod tad-demm, bidliet fl-għadd ta' ċelluli ħomor tad-demm (osservati fittestijiet tad-demm) - Tnaqqis fil-livell ta' magnesium, phosphate, potassium, calcium jew sodium fid-demm, fluwidu żejjed, żieda ta' aċidu uriku jew lipidi fid-demm, tnaqqis fl-aptit, telf t'aptit, żieda fl-aċidità tad demm, bidliet oħra fl-imluħa tad-demm (osservati fit-testijiet tad-demm) - Sintomi ta' ansjetà, konfużjoni u diżorjentazzjoni, depressjoni, bidliet fil-burdata, ħmar il-lejl,
English: Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including tacrolimus.
Maltese: F'pazjenti kkurati b'immunosoppressanti, inkluż tacrolimus, kienu irrappurtati każijiet ta' nefropatija assoċjata mal-virus BK, kif ukoll każijiet ta' lewkoenċefalopatija multifokali progressiva (PMLprogressive multifocal leukoencephalopathy) assoċjata mal-virus JC.
English: Tacrolimus treatment can be considered in pregnant women when there is no safer alternative, and when the perceived benefit justifies the potential risk to the foetus.
Maltese: Kura b'tacrolimus tista' tiġi kkunsidrata f'nisa tqal meta ma jkunx hemm alternattiva aktar sikura, u meta l-benefiċċji maħsuba jiġġustifikaw ir-riskju potenzjali għallfetu.
English: Certain combinations of tacrolimus with substances known to have nephrotoxic or neurotoxic effects may increase the risk of these effects (see section 4.5).
Maltese: Ċerti kombinazzjonijiet ta' tacrolimus ma' sustanzi magħrufa li għandhom effetti nefrotossiċi jew newrotossiċi jistgħu jżidu r-riskju ta' dawn l-effetti (ara sezzjoni 4.5).
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom for which standard antibiotics do not work.
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: It contains the active substance dalbavancin.
Maltese: Fih is-sustanza attiva dalbavancin.
English: In the 3 studies, between 87% and 94% of patients treated with Xydalba were cured, compared with between 91% and 93% of patients treated with any of the two comparators.
Maltese: Fit-3 studji, bejn 87% u 94% tal-pazjenti kkurati b'Xydalba fiequ, meta mqabbel ma' bejn 91% u 93% tal-pazjenti kkurati bi kwalunkwe wieħed miż-żewġ komparaturi.
English: This is a summary of the European public assessment report (EPAR) for Xydalba.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Xydalba.
English: Dalbavancin has been shown to work against bacteria (such as methicillin resistant Staphylococcus aureus (MRSA))
Maltese: Iddalbavancin intweriet li taħdem kontra batterji (bħal Staphylococcus aureus reżistenti għall-metiċillina
English: The active substance in Xydalba, dalbavancin, is a type of antibiotic called glycopeptide.
Maltese: Is-sustanza attiva f'Xydalba, id-dalbavancin, hija tip ta' antibijotiku imsejjaħ glikopeptid.
English: Why is Xydalba approved?
Maltese: Għaliex ġie approvat Xydalba?
English: The recommended dose is 1,500 mg, given either as a single infusion or as 1,000 mg in the first week followed by 500 mg one week later.
Maltese: Id-doża rakkomandata hija ta' 1,500 mg, mogħtija jew bħala infużjoni unika jew bħala 1,000 mg fl-ewwel ġimgħa segwita b'500 mg ġimgħa wara.
English: These side effects were generally of mild or moderate severity.
Maltese: Dawn l-effetti sekondarji kienu ġeneralment ta' severità ħafifa jew moderata.
English: Xydalba was compared with vancomycin (another glycopeptide) or with linezolid (an antibiotic that can be taken by mouth) in three main studies involving a total of around 2,000 patients with serious infections of the skin and soft tissue under the skin, such as cellulitis, skin abscesses and wound infections.
Maltese: Xydalba tqabbel ma' vancomycin (glikopeptid ieħor) jew ma' linezolid (antibijotiku li jista' jittieħed millħalq) fi tliet studji ewlenin li invovlew total ta' madwar 2,000 pazjent b'infezzjonijiet serji tal-ġilda u ttessut artab ta' taħt il-ġilda, bħal ċellulite, axxessi tal-ġilda u infezzjonijiet fil-ġrieħi.
English: Xydalba is given once a week by an infusion lasting 30 minutes.
Maltese: Xydalba jingħata darba fil-ġimgħa b'infużjoni li ddum 30 minuta.
English: A list of bacteria against which Xydalba is active can be found in the summary of product characteristics (also part of the EPAR).
Maltese: Lista ta' batterji li Xydalba huwa attiv kontrihom tinstab fis-sommarju tal-karatteristiċi tal-prodott (parti wkoll mill-EPAR).
English: Xydalba is an antibiotic used in adults to treat acute (short-term) bacterial infections of the skin and of skin structures (tissue below the skin) such as cellulitis (inflammation of the deep skin tissue), skin abscesses and wound infections.
Maltese: Xydalba huwa antibijotiku li jintuża fl-adulti biex jiġu kkurati infezzjonijiet batteriċi akuti (għal żmien qasir) tal-ġilda u tal-istrutturi tal-ġilda (tessut taħt il-ġilda) bħal ċellulite (infjammazzjoni tat-tessut filfond fil-ġilda), axxessi tal-ġilda u infezzjonijiet fil-ġrieħi.
English: In light of the need for new antibiotics targeting multi-resistant bacteria, the CHMP concluded that Xydalba, which showed activity against certain bacteria resistant to other antibiotics, could be a valuable alternative treatment option.
Maltese: Fid-dawl talbżonn għal antibijotiċi ġodda li jimmiraw batterji multireżistenti, is-CHMP ikkonkluda li Xydalba, li wera attività kontra ċerti batterji li huma reżistenti għal antibijotiċi oħrajn, jista' jkun għażla ta' kura alternattiva siewja.
English: The full EPAR and risk management plan summary for Xydalba can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Għal aktar informazzjoni rigward il-kura bi Xydalba, aqra l-fuljett ta' tagħrif (parti wkoll mill-EPAR) jew ikkuntattja lit-tabib jew lill-ispiżjar tiegħek.
English: Other information about Xydalba
Maltese: Informazzjoni oħra dwar Xydalba
English: Xydalba's safety profile is comparable to that of other antibiotics of the glycopeptide class; side effects affecting hearing and kidney function, which are typical for glycopeptides, have not been shown with the proposed regimens of Xydalba in the clinical trials.
Maltese: Il-profil tas-sigurtà ta' Xydalba huwa paragunabbli ma' dak ta' antibijotiċi oħrajn tal-klassi tal-glikopeptidi; effetti sekondarji li jaffettwaw is-smigħ u l-funzjoni tal-kliewi, li huma tipiċi għall-glikopeptidi, ma ntwerewx bil-korsijiet proposti ta' Xydalba fil-provi kliniċi.
English: The most common side effects with Xydalba (which may affect between 1 and 3 people in 100) are nausea (feeling sick), diarrhoea and headache.
Maltese: L-effetti sekondarji l-aktar komuni bi Xydalba (li jistgħu jaffettwaw bejn persuna 1 u 3 persuni minn kull 100) huma nawżja (tħossok ma tiflaħx), dijarea u wġigħ ta' ras.
English: What are the risks associated with Xydalba?
Maltese: X'inhu Xydalba u għal xiex jintuża?
English: How does Xydalba work?
Maltese: Kif jintuża Xydalba?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Xydalba on 19 February 2015.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Xydalba fid-19 ta' Frar 2015.
English: The full EPAR for Rekovelle can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Rekovelle
Maltese: Informazzjoni oħra dwar Rekovelle
English: Rekovelle contains the active substance follitropin delta.
Maltese: Rekovelle fih is-sustanza attiva follitropin delta.
English: Why is Rekovelle approved?
Maltese: Għaliex ġie approvat Rekovelle?
English: The study showed that Rekovelle was as effective as GONAL-f at stimulating the ovaries: around 31% of women (204 out of 665) treated with Rekovelle became pregnant compared with around 32% of women (209 out of 661) treated with GONAL-f. Implantation rates were also similar: around 35% with Rekovelle versus around 36% with GONAL-f.
Maltese: L-istudju wera li Rekovelle kien effettiv bħala GONAL-f fl-istimulazzjoni tal-ovarji: madwar 31 % tannisa (204 minn 665) ikkurati b'Rekovelle inqabdu tqal meta mqabbla ma' madwar 32 % tan-nisa (209 minn 661) ikkurati b'GONAL-f.
English: The frequency of side effects may decrease with repeated treatment cycles.
Maltese: Il-frekwenza tal-effetti sekondarji tista' tonqos b'ċikli ta' kura ripetuti.
English: The safety profile of Rekovelle was considered acceptable and similar to that of GONAL-f.
Maltese: Il-profil tas-sigurtà ta' Rekovelle tqies aċċettabbli u simili għal dak ta' GONAL-f.
English: This is a summary of the European public assessment report (EPAR) for Rekovelle.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Rekovelle.
English: What are the risks associated with Rekovelle?
Maltese: X'inhuma r-riskji assoċjati ma' Rekovelle?
English: Rekovelle was compared with GONAL-f (follitropin alfa), another fertility medicine, in one study involving 1,326 women who were undergoing controlled ovarian stimulation for IVF or ICSI.
Maltese: Rekovelle tqabbel ma' GONAL-f (follitropin alfa), mediċina oħra tal-fertilità, fi studju wieħed li kien jinvolvi 1,326 mara li kienu għaddejjin minn stimulazzjoni kkontrollata tal-ovarji għall-IVF jew l-ICSI.
English: Rekovelle follitropin delta
Maltese: Sommarju tal-EPAR għall-pubbliku follitropin delta
English: The most common side effects with Rekovelle (which may affect between 1 and 10 people in 100) are headache, discomfort and pain in the pelvic area which may arise from the ovaries, nausea (feeling sick) and tiredness and ovarian hyperstimulation syndrome (OHSS).
Maltese: L-effetti sekondarji l-aktar komuni b'Rekovelle (li jistgħu jaffettwaw bejn persuna 1 u 10 persuni minn kull 100) huma uġigħ ta' ras, skumdità u uġigħ fil-parti pelvika li jistgħu jkunu kkawżati mill-ovarji, dardir (tħossok ma tiflaħx) u għeja u sindromu ta' iperstimulazzjoni ovarja (OHSS, ovarian hyperstimulation syndrome).
English: Rekovelle is a medicine given to women who are having fertility treatments such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).
Maltese: Rekovelle huwa mediċina mogħtija lil nisa li jkunu qed jieħdu kuri tal-fertilità bħall-fertilizzazzjoni in vitro (IVF, in vitro fertilisation) jew l-injezzjoni tal-isperma intraċitoplasmika (ICSI, intracytoplasmic sperm injection).
English: The active substance in Rekovelle, follitropin delta, is a copy of the natural hormone called folliclestimulating hormone (FSH) which plays a key role in fertility in women by stimulating the production of eggs in the ovaries.
Maltese: Is-sustanza attiva f'Rekovelle, il-follitropin delta, hija kopja tal-ormon naturali msejjaħ ormon stimulanti tal-follikuli (FSH) li għandu rwol ewlieni fil-fertilità fin-nisa billi jistimula l-produzzjoni talbajd fl-ovarji.
English: How is Rekovelle used?
Maltese: Kif jaħdem Rekovelle?
English: What is Rekovelle and what is it used for?
Maltese: X'inhuma l-benefiċċji ta' Rekovelle li ħarġu mill-istudji?
English: For the full list of all side effects reported with Rekovelle, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati b'Rekovelle, ara l-fuljett ta' tagħrif.
English: Rekovelle must not be used in women with tumours of the pituitary gland or hypothalamus, or cancer of the breast, womb or ovary.
Maltese: Rekovelle m'għandux jintuża f'nisa b'tumuri tal-glandola pitwitarja jew tal-ipotalamu, jew b'kanċer tassider, tal-ġuf jew tal-ovarji.
English: EMEA/H/C/001244
Maltese: 20 ta' Jannar 2011 EMA/13310/2011 EMEA/H/C/001244
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Tekinex can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Maltese: Is-sommarju tal-opinjoni tal-Kumitat għal Prodotti Mediċinali Orfni għal Tekinex huwa disponibbli fis-sit tal-Aġenzija ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
English: Tekinex is a medicine that contains the active substance omacetaxine mepesuccinate.
Maltese: Tekinex huwa mediċina li fiha s-sustanza attiva omacetaxine mepesuccinate.
English: It is derived from harringtonine, a substance extracted from a Chinese evergreen.
Maltese: Din ġejja minn harringtonine, sustanza estratta minn evergreen Ċiniża.
English: What is Tekinex?
Maltese: X'inhu Tekinex?
English: The application was withdrawn at ‘day 120'.
Maltese: L-applikazzjoni kienet waslet f'‘jum 120' meta ġiet irtirata.
English: The active substance in Tekinex, omacetaxine, is an inhibitor of protein synthesis.
Maltese: Is-sustanza attiva f'Tekinex, omacetaxine, hija inibitur tas-sintesi tal-proteini.
English: On 11 January 2011, ChemGenex Europe SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Tekinex intended to be used to treat patients with Philadelphia chromosome-positive chronic myeloid leukaemia who have the ‘Bcr-Abl T315I kinase domain' mutation and whose previous treatment with imatinib had failed.
Maltese: Fil-11 ta' Jannar 2011, ChemGenex Europe SAS għarrfet uffiċjalment lill-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) bl-intenzjoni li tirtira l-applikazzjoni tagħha għallawtorizzazzjoni għat-tqegħid fis-suq għal Tekinex maħsub sabiex jintuża fil-kura ta' pazjenti b'lewkimja majelojde kronika pożittiva għall-kromosoma ta' Philadelphia li għandhom il-mutazzjoni tad-‘domain tal-kinase Bcr-Abl T315I' u li l-kura li ħadu fil-passat b'imatinib ma kinitx ta' suċċess.
English: Tekinex was therefore expected to work in Ph+ patients with the T315I mutation.
Maltese: Għaldaqstant, Tekinex kien mistenni li jaħdem f'pazjenti Ph+ li għandhom il-mutazzjoni T315I.
English: Because the number of patients with CML is low, the disease is considered ‘rare', and Tekinex was designated an ‘orphan medicine' (a medicine used in rare diseases) on 2 September 2004.
Maltese: Minħabba li n-numru ta' pazjenti bis-CML huwa wieħed baxx, il-marda hija kkunsidrata bħala waħda ‘rari', u fit-2 ta' Settembru 2004, Tekinex kien ikklassifikat bħala ‘mediċina orfni' (mediċina li tintuża f'mard rari).
English: The way it works is unclear, but it is thought to disrupt the production of the Bcr-Abl tyrosine kinase enzyme.
Maltese: Il-mod ta' kif taħdem mhuwiex ċar, iżda huwa maħsub li tfixkel il-produzzjoni tal-enzima tyrosine kinase Bcr-Abl.
English: It was to be used in patients whose previous treatment with imatinib (another anticancer medicine) had failed, possibly due to a mutation in the gene for the Bcr-Abl kinase called the ‘T315I mutation'.
Maltese: Kien se jintuża f'pazjenti li l-kura preċedenti tagħhom b'imatinib (mediċina oħra kontra l-kanċer) ma kinitx ta' suċċess, probabbli minħabba mutazzjoni fil-ġene tal-Bcr-Abl kinase imsejjaħ ‘il-mutazzjoni T315I'.
English: Other medicines known as tyrosine kinase inhibitors, including imatinib, act in CML by attaching directly to the Bcr-Abl tyrosine kinase enzyme.
Maltese: Mediċini oħra magħrufa bħala inibituri ta' tyrosine kinase, li jinkludu imatinib, jaġixxu fis-CML billi jeħlu direttament mal-enzima tyrosine kinase Bcr-Abl.
English: The letter from the company notifying the Agency of the withdrawal of the application is available under the tab ‘All documents'.
Maltese: L-ittra mill-kumpanija li tgħarraf lill-Aġenzija bl-irtirar tal-applikazzjoni tinsab taħt it-tab ‘Dokumenti kollha'.
English: The company presented results from a main study involving 66 patients with Philadelphia-positive CML and the T315I mutation, whose previous treatment with imatinib had failed.
Maltese: Il-kumpanija ppreżentat riżultati minn studju prinċipali li fih ħadu sehem 66 pazjent b'CML pożittiva għall-Philadelphia u għal-mutazzjoni T315I, li l-kura li kienu ħadu qabel b'imatinib ma kinitx ta' suċċess.
English: What was Tekinex expected to be used for?
Maltese: Għalxiex kien mistenni li jintuża Tekinex?
English: Tekinex was expected to be used to treat adults with ‘Philadelphia chromosome positive' (Ph+) chronic myeloid leukaemia (CML, a cancer of a type of white blood cells called granulocytes).
Maltese: Tekinex kien mistenni li jintuża fil-kura ta' adulti b'lewkimja majelojde kronika ‘pożittiva għallkromosoma ta' Philadelphia ' (Ph+) (CML, kanċer ta' tip ta' ċelloli bojod tad-demm li jissejħu granuloċiti ). Ph+ ifisser li xi wħud mill-ġeni tal-pazjent ikunu rranġaw ruħhom b'tali mod li jiffurmaw kromożoma speċjali li tissejjaħ kromożoma ta' Philadelphia li tipproduċi enzima, Bcr-Abl kinase li twassal għall-iżvilupp tal-lewkimja.
English: This means that the CHMP had evaluated the initial documentation provided by the company and formulated a list of questions.
Maltese: Dan ifisser li s-CHMP kien evalwa ddokumentazzjoni inizjali pprovduta mill-kumpanija u fassal lista ta' mistoqsijiet.
English: The T315I mutation changes certain properties of the enzyme, making it harder for these medicines to attach to it. Because omacetaxine does not act in this way, its action is not affected by the T315I mutation.
Maltese: Il-mutazzjoni T315I tbiddel xi wħud mill-karatteristiċi tal-enzima, u tagħmilha iktar diffiċli għall-mediċini biex jeħlu magħha.
English: Tekinex was not compared directly with any other treatment.
Maltese: Tekinex ma tqabbilx direttament ma' kura oħra.
English: The CHMP was of the view that the medicine's benefits were uncertain.
Maltese: Is-CHMP kien tal-opinjoni li l-benefiċċji tal-mediċina kienu inċerti.
English: It was to be available as a powder to be made up into a solution for injection.
Maltese: Kien se jkun disponibbli bħala trab magħmul għal soluzzjoni għal injezzjoni.
English: Str. Stadionului nr.
Maltese: Stadionului nr. 1
English: Member state/EEA
Maltese: Stat Membru/ EEA
English: 90 The Broadway Chesham
Maltese: 90 The Broadway
English: Laboratoires Biové 3 rue de Lorraine 62510 Arques FRANCE
Maltese: Laboratoires Biové 3 rue de Lorraine 62510
English: Zone Industrielle des Touches 200, avenue de Mayenne
Maltese: 200, avenue de Mayenne
English: Denmark Ceva Animal Health A/S
Maltese: Id-Danimarka Ceva Animal Health A/S
English: Ceva Saúde Animal - Produtos Farmacêuticos e Farmacológicos, Lda Rua Doutor António Loureiro Borges, 9/9A - 9°A Miraflores
Maltese: Farmacêuticos e Farmacológicos, Lda Rua Doutor António Loureiro Borges, 9/9A - 9°A
English: CEVA SANTE ANIMALE ROMANIA SRL
Maltese: Ir-Rumanija CEVA SANTE ANIMALE ROMANIA SRL
English: COLIVET sol. ad us.vet.
Maltese: ad us.vet.
English: IU/ML/DIVASA -FARMANIC
Maltese: IU/ML/DIVASAFARMANIC
English: CVMP Note for guidance: Approach towards harmonisation of withdrawal periods http://www.emea.europa.eu/pdfs/vet/swp/003695en.pdf
Maltese: tiżmim http://www.emea.europa.eu/pdfs/vet/swp/003695en.pdf
English: Oral administration treatment: 3 - 4 days
Maltese: Amministrazzjoni orali trattament: 3 - 4 jiem
English: 3 days.
Maltese: 3 jiem.
English: 1 Commission Regulation (EC) NO 1177/2006 of 1 August 2006 implementing Regulation (EC) No 2160/2003 of the European Parliament and of the Council as regards requirements for the use of specific control methods in the framework of the national programmes for the control of Salmonella in poultry (OJ L 212, 2.8.2006, p.3).http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:212:0003:0005:EN:PDF
Maltese: 1 Ir-Regolament tal-Kummissjoni (KE) Nru 1177/2006 tal-1 ta' Awwissu ta' 2006 li jimplimenta r-Regolament (KE) Nru 2160/2003 tal-Parlament Ewropew u tal-Kunsill fir-rigward tal-kundizzjonijiet għall-użu ta' metodi speċifiċi talkontroll fil-qafas tal-programmi nazzjonali għall-kontroll tas-salmonella fit-tjur (ĠU L 212, 2.8.2006, p.3).http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:212:0003:0005:EN:PDF
English: 44153 Ancenis Cedex
Maltese: 44153 Ancenis Cedex FRANCE
English: The only area of potential risks identified was the risk of lack of efficacy in case of invasive strains and the possibility of interference with Salmonella control programs.
Maltese: riskji potenzjali identifikati kien ir-riskju ta' nuqqas ta' effikaċja f'każ ta' razez invażivi u l possibbiltà ta' interferenza mal-programmi ta' kontroll tas-Salmonella.
English: COLISTINE SULFATE 2 MUI /ML BUVABLE VIRBAC
Maltese: 2 MUI /ML BUVABLE VIRBAC
English: Applicant/ Marketing Authorisation Holder
Maltese: U APPLIKANTI/DETENTURI
English: Animal species
Maltese: Ceva Saúde AnimalProdutos
English: This group of antibiotics has a polypeptide structure, with mainly bactericide activity and a medium antibacterial spectrum, which covers gram-negative microorganisms only.
Maltese: Dan il-grupp ta' antibijotiċi għandu struttura polipeptida, prinċipalment b'attività batteriċida u bi spettru antibatteriku medju, li jkopri biss mikroorganiżmi gram-negattivi.
English: 37075 Tours Cedex
Maltese: 37075 Tours Cedex 2 FRANCE
English: CENAVISA, S.A. Camí Pedra Estela S/N
Maltese: Ir-Rumanija CENAVISA, S.A. Camí Pedra Estela S/N 43205 Reus
English: Lithuania Ceva Santé Animale Zone Industrielle La Ballastiere
Maltese: Il-Polonja Ceva Santé Animale Zone Industrielle La Ballastiere
English: Coliscour, oral solution of colistin sulphate 2
Maltese: Coliscour, oral solution of colistin sulphate 2 MIU/ml
English: The data packages submitted consist of bibliographic data, available in the public domain, and proprietary data.
Maltese: Il-pakketti tad-dejta sottomessi jikkonsistu f'dejta biblijografika, disponibbli fil-qasam pubbliku, u dejta tal-fabbrikant.
English: Colistin sulfate is a polypeptide antibiotic belonging to the polymyxins group of antibiotics.
Maltese: Colistin sulfate huwa antibijotiku polipeptid li jagħmel parti mill-grupp polimiksini tal-antibijotiċi.
English: Poultry: 3 days
Maltese: Tjur: 3 jiem
English: Colivet 2 000 000 UI /ml, concentrate for oral solution for pigs and birds
Maltese: 2 000 000 UI /ml, concentrate for oral solution for pigs and birds
English: For oral administration, usually via drinking water.
Maltese: Għal amministrazzjoni orali, normalment permezz tal-ilma taxxorb.
English: (0,37 ml product/10 kg b.w.
Maltese: (0,37 ml prodott/10 kg b.w.
English: Ceva Animal Health Ltd
Maltese: Ir-Renju Unit Ceva Animal Health Ltd
English: SOGECOLI 2 MILLIONS UI/ML
Maltese: COLIVET 2,000,000 UI/ML
English: COLISCOUR 2
Maltese: SOGECOLI 2
English: Pigs: 50 000 IU colistine sulfate/kg b.w.
Maltese: Majjali: 50 000 IU colistine sulfate/kg b.w.
English: Zone industrielle d'Etriche Route d'Avire, BP
Maltese: Zone industrielle d'Etriche
English: Cattle (calves), sheep (lambs), swine and chickens
Maltese: water for Cattle, Sheep, Swine and Chickens konsekuttivi.
English: 53022 Laval Cedex
Maltese: 53022 Laval Cedex 9 FRANCE
English: Chickens: 75 000 IU colistine sulfate/kg b.w.
Maltese: Tiġieġ: 75 000 IU colistine sulfate/kg b.w.
English: Broilers chickens: 7 days
Maltese: Brojlers tiġieġ: 7 jiem
English: Benefit Risk Assessment
Maltese: Stima ta' Benefiċċju Riskju
English: IU/ml, concentrate for oral solution, pigs, poultry
Maltese: IU/ml, Konzentrat für eine orale Lösung für Schweine und Geflügel
English: Calves and Lambs: 100 000
Maltese: Majjali: 100 000
English: IU/ml koncentrát na perorálny roztok na použitie v pitnej vode pre hovädzí dobytok, ovce, ošípané a kurčatá
Maltese: COLIPLUS 2 000 000 IU/ml koncentrát na perorálny roztok na použitie v pitnej vode pre hovädzí dobytok, ovce, ošípané a kurčatá
English: 5 Chindiei , sector 4 040185 Bucharest ROMANIA
Maltese: 5 Chindiei , sector 4